

8 July 2021

**LungLife AI, Inc.
("LungLife" or the "Company")**

Director/PDMR Notification

LungLife (AIM: LLAI), the developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces that it has been notified of the following transaction in the Company's common shares of US \$0.0001 each ("Common Shares") undertaken by directors.

The transactions were made in connection with the placing of new Common Shares in the capital of the Company as part of the Company's admission to trading on AIM.

Roy Davis, Non-Executive Chair, has today purchased 14,204 Common Shares at the placing price of 176.0 pence per share. Following this purchase, Mr Davis now holds 14,204 Common Shares, representing approximately 0.06% of the outstanding share capital of the Company.

In addition, Andrew Boteler, Non-Executive Director, has today purchased 5,681 Common Shares at the placing price of 176.0 pence per share. Following this purchase, Mr Boteler now holds 5,681 Common Shares, representing approximately 0.02% of the outstanding share capital of the Company.

The following disclosures are made in accordance with the requirements of the UK Market Abuse Regulation.

1	Details of the person discharging managerial responsibilities / person closely associated		
a)	Name	1) Roy Davis 2) Andrew Boteler	
2	Reason for the notification		
a)	Position/status	1) Non-Executive Chairman 2) Non-Executive Director	
b)	Initial notification /Amendment	1) Initial notification 2) Initial notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	LungLife AI, Inc.	
b)	LEI	549300VBVDIF0Y3OVI38	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument Identification code	Common shares of \$0.0001 each in the capital of the Company ISIN: USU5500L1045	
b)	Nature of the transaction	Purchase of Common Shares	
c)	Price(s) and volume(s)	Price	No. of shares
		1) 176.0p 2) 176.0p	1) 14,204 2) 5,681
d)	Aggregated information - Aggregated volume - Price	N/a - single transaction	

e)	Date of the transaction	8 July 2021
f)	Place of the transaction	London Stock Exchange, AIM

- Ends -

For further information please contact:

LungLife AI, Inc.

Paul Pagano, CEO
David Anderson, CFO

www.lunglifeai.com

Via Walbrook PR

Investec Bank plc (Nominated Adviser & Broker)

Daniel Adams / Virginia Bull / Cameron MacRitchie

Tel: +44 (0)20 7597 5970

Walbrook PR Limited

Paul McManus / Alice Woodings

Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com

Mob: 07980 541 893 / 07407 804 654